Keyur Patel Selected Research

cilofexor

6/2022	IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
1/2021	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
1/2020	Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keyur Patel Research Topics

Disease

41	Chronic Hepatitis C 10/2016 - 03/2002
40	Fibrosis (Cirrhosis) 01/2022 - 03/2002
33	Infections 01/2022 - 03/2002
22	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2013
21	Neoplasms (Cancer) 05/2022 - 05/2013
17	Hepatitis C 01/2019 - 11/2002
15	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 03/2003
13	Non-alcoholic Fatty Liver Disease 04/2022 - 05/2010
9	Inflammation (Inflammations) 01/2022 - 03/2002
8	Disease Progression 12/2016 - 11/2002
7	Wounds and Injuries (Trauma) 02/2022 - 10/2016
7	Liver Diseases (Liver Disease) 12/2021 - 01/2006
6	Anemia 01/2022 - 11/2003
6	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2021 - 11/2015
6	Insulin Resistance 01/2019 - 10/2009
5	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 05/2006
5	Virus Diseases (Viral Diseases) 08/2012 - 02/2004
4	Philadelphia Chromosome 10/2021 - 03/2017
4	Hemolytic Anemia 02/2014 - 10/2010
3	Pruritus (Itching) 06/2022 - 01/2020
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 03/2017
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 01/2019
3	Autoimmune Diseases (Autoimmune Disease) 09/2021 - 01/2006
3	Ulcer 05/2021 - 02/2021
3	Tuberous Sclerosis (Bourneville's Disease) 10/2017 - 11/2016
3	Inborn Genetic Diseases (Disease, Hereditary) 10/2017 - 11/2016
3	Residual Neoplasm 04/2017 - 01/2016
3	Body Weight (Weight, Body) 05/2013 - 03/2002
2	Isochromosomes 05/2022 - 01/2022
2	Cataract (Cataracts) 01/2022 - 01/2021
2	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
2	Leukocytosis (Pleocytosis) 01/2022 - 01/2017
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021 - 03/2017
2	Diabetic Foot 05/2021 - 02/2021
2	Renal Insufficiency (Renal Failure) 01/2021 - 07/2005
2	B-Cell Lymphoma (Lymphoma, B Cell) 09/2020 - 01/2019

Drug/Important Bio-Agent (IBA)

23	Biomarkers (Surrogate Marker)IBA 06/2022 - 12/2004
21	Ribavirin (Virazole)FDA LinkGeneric 10/2016 - 03/2002
17	InterferonsIBA 01/2019 - 03/2002
17	Antiviral Agents (Antivirals)IBA 01/2018 - 10/2002
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2004
9	Alanine Transaminase (SGPT)IBA 01/2021 - 03/2002
8	RNA (Ribonucleic Acid)IBA 05/2013 - 03/2002
6	Biological ProductsIBA 05/2022 - 07/2002
6	Interferon-alpha (Interferon Alfa)IBA 02/2012 - 05/2004
4	venetoclaxIBA 01/2022 - 01/2019
4	farglitazarIBA 01/2022 - 04/2010
4	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2016
4	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 01/2018
4	CytokinesIBA 11/2018 - 06/2006
4	LipidsIBA 12/2016 - 06/2010
4	SofosbuvirIBA 10/2016 - 05/2013
4	Inosine TriphosphataseIBA 02/2014 - 10/2010
3	cilofexorIBA 06/2022 - 01/2020
3	ImmunosorbentsIBA 01/2022 - 10/2009
3	Collagen Type III (Type III Collagen)IBA 01/2022 - 02/2015
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2016
3	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 10/2014
3	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 01/2021
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2018
3	ibrutinibIBA 12/2021 - 01/2019
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 01/2016
3	Pharmaceutical PreparationsIBA 09/2021 - 02/2006
3	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2020 - 10/2010
3	Complement C3 (C3 Complement)IBA 01/2019 - 02/2015
3	Janus Kinase 2IBA 01/2019 - 05/2013
3	ruxolitinibIBA 01/2018 - 05/2013
3	trans-sodium crocetinate (crocetin)IBA 10/2017 - 11/2016
3	fms-Like Tyrosine Kinase 3IBA 04/2017 - 01/2016
3	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2017 - 10/2014
3	Peptides (Polypeptides)IBA 02/2015 - 02/2006
3	Hyaluronic Acid (Hyaluronan)IBA 12/2014 - 03/2003
3	Pregnancy-Associated alpha 2-Macroglobulins (alpha 2 Macroglobulin)IBA 12/2014 - 12/2004
3	CholesterolIBA 07/2012 - 06/2010
3	Interferon LambdaIBA 12/2010 - 06/2010
2	CreatinineIBA 04/2022 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 04/2022 - 09/2017
2	Decitabine FDA Link 01/2022 - 10/2017
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2021
2	Monoclonal AntibodiesIBA 01/2022 - 02/2009
2	EnzymesIBA 01/2022 - 12/2014
2	Interleukin-2 (IL2)IBA 01/2022 - 12/2014
2	SuspensionsIBA 01/2022 - 01/2021
2	Adenosine Triphosphate (ATP)IBA 12/2021 - 01/2019
2	fludarabineIBA 12/2021 - 10/2014
2	Drug CombinationsIBA 01/2021 - 01/2011
2	CollagenIBA 01/2021 - 01/2019
2	BilirubinIBA 01/2021 - 09/2018
2	Bile Acids and Salts (Bile Acids)IBA 01/2021 - 01/2020
2	Keratin-18 (Keratin 18)IBA 01/2021 - 05/2014
2	NucleophosminIBA 01/2019 - 11/2016

Therapy/Procedure

64	Therapeutics 06/2022 - 03/2002
14	Drug Therapy (Chemotherapy) 01/2022 - 08/2013
10	Liver Transplantation 08/2022 - 07/2005
3	Transplantation 12/2021 - 01/2017
3	Precision Medicine 12/2021 - 04/2014
3	Aftercare (After-Treatment) 01/2021 - 03/2003
3	Stem Cell Transplantation 07/2020 - 01/2016
2	Surgical Amputation (Amputations) 05/2021 - 02/2021
2	Immunotherapy 09/2020 - 01/2017